Department of Cardiovascular Surgery, Hyogo Prefectural Amagasaki General Medical Center, 2-17-77, Higashinaniwa-cho, Amagasaki, Hyogo, 660-8550, Japan.
Gen Thorac Cardiovasc Surg. 2024 Apr;72(4):216-224. doi: 10.1007/s11748-023-01966-z. Epub 2023 Aug 5.
This study investigated early and late outcomes between ascending aorta/partial arch replacement and total arch replacement with entry resection in DeBakey type I acute aortic dissection (DIAAD) repair.
This study included 98 patients who underwent DIAAD repair from January 2005 to December 2020. Seventy-four patients underwent ascending aorta and partial arch replacement with entry resection (Non-TAR group), and 24 underwent total arch replacement with entry resection (TAR group). The mean follow-up period was 4.8 ± 3.2 years. The follow-up rate was 92.3%. The mean age in the Non-TAR and TAR groups was 68.8 ± 10.4 years and 61.6 ± 13.7 years, respectively (P = 0.046). No difference in preoperative shock and malperfusion syndrome was observed between the groups. Hospital death was observed in 5.4% and 12.5% of the Non-TAR and TAR groups, respectively (P = 0.241). Postoperative permanent neurologic deficits and temporary hemodialysis were more frequently seen in the TAR compared to the Non-TAR group (P = 0.03 and 0.003, respectively). The 5-year survival rates were 95.1% ± 3.4% and 89.2% ± 7.2% in the Non-TAR and TAR groups, respectively (Log-rank P = 0.603). Freedom from downstream aorta-related reinterventions at 5 years was 87.8% ± 4.5% and 64.1% ± 11.0% in the Non-TAR and TAR groups, respectively (Log-rank P = 0.007). Three patients in each group underwent thoracic endovascular aortic repair for residual aortic dissection.
Early and late outcomes in the Non-TAR group were satisfactory compared to those in the TAR group. Entry resection with graft replacement remains a standard approach in DIAAD repair.
本研究旨在比较升主动脉/部分弓置换联合窦部切开术与全弓置换联合窦部切开术治疗 DeBakey Ⅰ型急性主动脉夹层(DIAAD)的早期和晚期结果。
本研究纳入了 2005 年 1 月至 2020 年 12 月期间接受 DIAAD 修复的 98 例患者。74 例患者接受升主动脉和部分弓置换联合窦部切开术(非 TAR 组),24 例患者接受全弓置换联合窦部切开术(TAR 组)。平均随访时间为 4.8±3.2 年。随访率为 92.3%。非 TAR 组和 TAR 组的平均年龄分别为 68.8±10.4 岁和 61.6±13.7 岁(P=0.046)。两组患者术前休克和灌注不良综合征无差异。非 TAR 组和 TAR 组的院内死亡率分别为 5.4%和 12.5%(P=0.241)。TAR 组术后永久性神经功能缺损和临时血液透析的发生率高于非 TAR 组(P=0.03 和 0.003)。非 TAR 组和 TAR 组的 5 年生存率分别为 95.1%±3.4%和 89.2%±7.2%(Log-rank P=0.603)。非 TAR 组和 TAR 组的 5 年下游主动脉相关再介入率分别为 87.8%±4.5%和 64.1%±11.0%(Log-rank P=0.007)。每组各有 3 例患者因残余主动脉夹层而行胸主动脉腔内修复术。
与 TAR 组相比,非 TAR 组的早期和晚期结果令人满意。窦部切开联合移植物置换仍然是 DIAAD 修复的标准方法。